Bli medlem
Bli medlem

Du är här

2016-10-25

BioGaia: BioGaia AB - Interim management statement 1 January - 30 September 2016

Comments from the Managing Director:
"Third quarter sales were driven by strong growth in Asia and Europe,
where the launch of EasyDropper is continuing. Net sales for the
first nine months reached SEK 395.9 million. It is highly gratifying
that we have now passed the level for 2015, in spite of the major
inventory build-up in Brazil last year. Promising is also the trend
in Business Unit Adult Health, which has shown growth for two
consecutive quarters. I would also like to mention that the clinical
study on reduction of pregnancy gingivitis, which we have previously
reported on, has been very well received by our partners, and it is
very satisfying that we have signed a sales agreement in Western and
Eastern Africa", says Axel Sjöblad, Managing Director of BioGaia AB.

Period from 1 January - 30 September 2016
(Figures in brackets refer to the same period of last year. The
comparative figures in the balance sheet refer to 31 December 2015)

· Net sales amounted to SEK 395.9 million (378.9), an increase of
SEK 17.0 million (4%). (No material foreign exchange effects arose.)

· Net sales in Business Unit Paediatrics reached SEK 313.8 million
(313.0), an increase of SEK 0.8 million (0 %). (No material foreign
exchange effects arose.)

· Net sales in Business Unit Adult Health amounted to SEK 69.4
million (54.6), an increase of SEK 14.8 million (27%) (excluding
foreign exchange effects, 24%).

· Operating profit excluding the distributed former subsidiary IBT
was SEK 153.1 million (140.8), an increase of SEK 12.3 million (9%).
Including IBT, operating profit was SEK 147.9 million (124.7). (No
material foreign exchange effects arose.)

· Profit after tax excluding IBT was SEK 112.4 million (112.2), an
increase of SEK 0.2 million (0%).

· Earnings per share from continuing operations totalled SEK 6.48
(6.49). Earnings per share including discontinued operations totalled
SEK 10.42 (5.76).

· The period's cash flow was SEK -27.6 million (8.0). Cash and cash
equivalents at 30 September 2016 amounted to SEK 201.6 million
(226.9). Cash flow includes the distribution of the subsidiary IBT,
which had a negative impact on cash flow of SEK 37.6 million.

Third quarter 2016

· Net sales amounted to SEK 126.0 million (106.0), an increase of
SEK 20.0 million (19%) (excluding foreign exchange effects, 17%).

· Net sales in Business Unit Paediatrics reached SEK 99.0 million
(88,9), an increase of SEK 10.1 million (11%) (no material foreign
exchange effects arose).

· Net sales in Business Unit Adult Health amounted to SEK 22.6
million (12.6), an increase of SEK 10.0 million (79%) (excluding
foreign exchange effects, 70%).

· Operating profit excluding IBT was SEK 48.4 million (36.2), an
increase of SEK 12.2 million (34 %). Including IBT, operating profit
was SEK 48.4 million (29.7). (No material foreign exchange effects
arose.)

· Profit after tax excluding IBT was SEK 35.1 million (25.7), an
increase of SEK 9.4 million (37%). Including IBT, profit after tax
was SEK 35.1 million (20.7).

· Earnings per share excluding IBT totalled SEK 2.02 (1.49).
Earnings per share including IBT totalled SEK 2.02 (1.19).

Key events in the third quarter of 2016

· Publication of study showing that BioGaia ProDentis reduces
pregnancy gingivitis.

· Agreement for the sale of drops, tablets and oral rehydration
solution in Kenya, Nigeria and Ghana.

Teleconference: You are welcome to take part in a teleconference on
the interim management statement that will be held today 25 October
at 8:45 a.m. by Managing Director Axel Sjöblad. To participate in the
teleconference call please see www.biogaia.com/agenda for telephone
numbers. The teleconference can also be followed at
https://wonderland.videosync.fi/biogaia-q3-report.

This information is information that BioGaia AB is obliged to make
public pursuant to the EU Market Abuse Regulation. The information
was submitted for publication, through the agency of the contact
person set out above, at 25 October 2016, 8:00 a.m. CET.

This is a translation of the Swedish version of the interim report.
When in doubt, the Swedish wording shall prevail.

For additional information contact:
Axel Sjöblad, Managing Director, BioGaia AB, telephone 46 8-555 293 00
or Margareta Hagman, Executive Vice President, BioGaia AB, telephone
46 8-555 293 00

BioGaia AB Box 3242, SE-103 64 STOCKHOLM
Street address: Kungsbroplan 3A, Stockholm
Telephone: 46 8-555 293 00, Corp. Identity no. 556380-8723
www.biogaia.com

BioGaia is a healthcare company that develops, markets and sells
probiotic products with documented health benefits. The products are
primarily based on the lactic acid bacterium Lactobacillus reuteri
which has probiotic, health- enhancing effects. The class B share of
the Parent Company BioGaia AB is quoted on the Mid Cap list of the
Nasdaq OMX Nordic Exchange Stockholm. www.biogaia.com.

BioGaia AB Box 3242. SE-103 64 STOCKHOLM Street address: Kungsbroplan
3A, Stockholm Telephone: +46 8 555 293 00, Corp. identity no.
556380-8723. www.biogaia.com.

-----------------------------------------------------------
http://news.cision.com/biogaia/r/biogaia-ab---interim-management-stateme...
http://mb.cision.com/Main/3271/2107674/579417.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.